A Novel Type 2A von Willebrand Factor Mutation Located at the Last Nucleotide of Exon 26 (3538G>A) Causes Skipping of Two Non-Adjacent Exons Introduction
Von Willebrand disease (VWD) is the most common inherited bleeding disorder known in humans, with published prevalence rates between 0.01% and 1%. 1, 2 The clinical spectrum of the disease is broad, ranging from mild mucocutaneous bleeding observed in Type 1 VWD (quantitative deficiency of von Willebrand factor -VWF) to severe, spontaneous bleeding in Type 3 VWD (complete absence of VWF). Type 2 VWD is characterized by the presence of qualitatively abnormal VWF and is a heterogeneous condition both phenotypically and genotypically. Four distinct subtypes are recognized. 3 Type 2A and Type 2B
VWD are characterized by the loss of high molecular weight VWF multimers;
however, these subtypes are best distinguished based on VWF interactions with platelets; this interaction is increased in Type 2B VWD as is observed by the enhanced ristocetin-induced platelet agglutination, and significantly reduced in Type 2A disease. Type 2M VWD refers to qualitatively abnormal variants with decreased platelet-dependent function not associated with the loss of highmolecular weight multimers. Type 2N VWD demonstrates defective binding of VWF to factor VIII.
The accurate discrimination of subtypes is important, particularly when it affects patient management. This has become easier since our understanding of the condition has progressed. However, challenging cases remain, particularly when the diagnosis is based on phenotypic data alone. Coagulation based laboratory tests vary over time within individuals, and an accurate diagnosis is sometimes difficult to achieve, even when repeated tests are performed. The only.
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The inheritance pattern of Type 2A VWD is usually autosomal dominant and significant progress has been made in defining the molecular genetic pathology of this subtype. Missense mutations account for the majority of Type 2A cases, and most are located within the region of exon 28 that encodes the A2 domain. Type 2A mutations have also been described at the C-terminus of the protein and in the D2 and A1 domains. Two distinct pathogenic sub-groups have been described within Type 2A VWD 8, 9 ; Group 1 is caused by defects in the synthesis and intracellular transport of multimers, and Group 2 results from an increase in plasma proteolysis of VWF by the ADAMTS13 protease following secretion into blood. Type 2A mutations can result in defective dimerization or multimerization and splicing defects found in the D3 domain leading to Type 2A have previously been described in abstract form. 10, 11 VWF undergoes extensive post-translational modifications by initially dimerizing through multiple intermolecular disulfide bonds between the carboxyl-terminal ends of the protein and then, once transported to the Golgi, forming interdimer disulfide bonds using cysteines found in the D3 domain. The resulting multimers range in size from 500 -20,000 kDa and it is the highest-molecular weight multimers that are most functionally active in terms of VWF's adhesive properties.
VWF is the largest soluble plasma protein. The VWF gene encompasses 178 kb of genomic DNA, and is comprised of 52 exons. Based on the number of only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From exons that have to be spliced together, it is not surprising that several splicing mutations resulting in various types of VWD have previously been described (http://www.shef.ac.uk/vwf/). Splicing defects are most often the result of a mutation in the 5' (donor) or 3' (acceptor) splice sites located at the exon/intron boundary, however, changes in the last nucleotide of an exon have also been shown to cause exon skipping in a number of conditions. [12] [13] [14] [15] [16] [17] [18] [19] In this study we describe a patient with a novel VWF mutation, 3538 G>A, which results in the inframe exon skipping of exon 26, and exons 23 and 26. To our knowledge, this is the first description of skipping of two non-adjacent exons as a pathogenic mechanism in VWD or any other condition.
Patients, materials and methods

Patients
The study family was submitted to the Canadian Type 1 VWD Study as a potential Type 1 VWD family. Each individual was informed of the experimental nature of the study and gave their informed consent. The study was approved by the Institutional Review Board at Queen's University, and at the source institution. To be eligible for the study at least one member from the family had to have a personal history of excessive mucocutaneous bleeding, von Willebrand factor antigen (VWF:Ag) and ristocetin cofactor activity (VWF:RCo) between 0.05 and 0.50 U/mL measured on at least 2 different samples. Whole blood samples for DNA extraction were collected in 3.2% sodium citrate (at a ratio of 9:1 vol/vol) from the index case and available immediate family members, and a plasma only.
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Coagulation studies
Laboratory tests for VWF:Ag, VWF:RCo and factor VIII coagulant activity (FVIII:C) were performed at the source clinic attended by the patient, and were repeated on different plasma samples at the Clinical Hemostasis Laboratory at Kingston General Hospital (Canada). All available laboratory results were averaged. In the source clinic laboratories, VWF:Ag and VWF:RCo values were assayed using the locally validated methodology. In the central laboratory, VWF:Ag was measured using the IMMUBIND VWF enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions (American Diagnostica, Greenwich, CT) . The VWF:RCo was measured by platelet aggregometry using freshly prepared, washed normal platelets, and the FVIII:C was measured using a one-stage assay. All measurements were made against a non-ABO-matched commercial reference plasma that was calibrated against the 91-666 or 97-586 World Health Organization (WHO) Plasma Standard. Ristocetin induced platelet aggregation (RIPA) was performed on a BIO/DATA Platelet Aggregometer, model PAP-4. VWF multimers were analyzed by electrophoresis using a 1.6% sodium dodecyl sulfate (SDS) agarose gel followed by electrotransfer to a nylon membrane. The multimers were visualized using the chemiluminescent visualization kit from Amersham Pharmacia Biotech (Baie D'Urfe, PQ, Canada). were wild-type and 17% were missing exon 26.
Expression and characterization of recombinant VWF:
To determine the effect of exon skipping on VWF structure and function, the patient's mRNA was amplified and the three spliced products (one normal and two exon-skipped transcripts) were introduced into the pCIneoVWFES expression vector containing the full-length VWF cDNA. The G1180R mutation was also examined to determine if this amino acid substitution could impair VWF 
To determine the effect of the mutations on VWF multimers, conditioned media from COS-7 cells for the homozygous wild-type, homozygous mutant and 50:50 heterozygous transfections was concentrated by dialysis and analyzed by SDS-agarose gel electrophoresis ( Figure 6 ). All sizes of multimers were observed for the G1180R recombinant protein, suggesting that this mutation does not impair multimerization. A full range of multimers were also observed in the media from the heterozygous transfections (involving wild-type and exonskipped cDNA constructs). Only the lowest molecular weight multimers are observed from recombinant protein missing exon 26 (homozygous) and the rVWF missing both exons 23/26 (homozygous) indicating that the missing cysteine residues are imperative in the formation of multimers.
DISCUSSION
In this report, we present a novel single base pair change at the last nucleotide of exon 26 that acts as the molecular basis for a young woman's Type 2A VWD. We have shown that this mutation results in skipping of not only exon 26, but also of exon 23 in a population of mutant transcripts. To the best of our knowledge, this is the first demonstration of multiple, non-adjacent exon skipping as the pathogenic basis for an inherited disease.
Splicing is a complicated process that involves the precise identification and joining of exons and removal of introns. For this to happen, five small nuclear (sn) RNAs (U1, U2 and U4-6) and more than 60 polypeptides must only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From correctly assemble into a large multicomponent ribonucleoprotein complex known as the spliceosome. 24, 25 The spliceosome recognizes conserved, consensus sequences including the 5' (donor site) and 3' (acceptor site) splice sites that flank mammalian exons. In addition to the donor and acceptor sites, the last 2 nucleotides of an exon are also semi-conserved; the second last is an "A" 64% of the time, and the last is a "G" 73% of the time. It is conceivable that changes to the last nucleotides of an exon might lead to aberrant splicing due to the donor site not being recognized by the splicesome complex. The mechanism by which the sequential pairing of splice sites is accomplished is not known, however the assembly of the spliceosome, while the RNA transcript is still being transcribed, is presumed to play a major role in the orderly pairing of appropriate splice sites. 26, 27 It is known that the splicing machinery associates with exons in a 5' to 3' order as they are synthesized, however, the covalent joining of exons does not necessarily proceed in a 5' to 3' direction due to inherent differences in rates of splicing catalysis between each exon pair. 28 In order to understand the transcript that is missing exon 26, we must examine the possibility that a change in the last nucleotide of an exon could lead to aberrant splicing. There are many precedents in the literature for this, all based on the idea that mutations at this site would lead to inactivation of the 5' donor splice site, and pairing of the donor site from one exon with the acceptor site of another, resulting in skipping of the adjacent exon. This has been described in a number of inherited diseases. 12 -19 The change in the last nucleotide of exon 26 is the only putative mutation identified in our patient, after only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From sequencing of the coding regions of exons 18-52 with flanking introns, and the vast majority of the introns surrounding the skipped exons (intron 22 was not completely sequenced because of its large size and the very low possibility that changes so far from the mutant exon might lead to exon skipping). In the patient's cDNA we only observed the 'G' at nucleotide position 3538, although it is possible that there are small, unappreciable amounts of the mutant 'A' allele present, which would produce the missense mutation G1180R. However, the expression studies on G1180R clearly show that it does not produce a Type 2A VWD phenotype and is not likely contributing to the patient's phenotype. This phenomenon, of a putative missense mutation leading instead to a splicing mutation, has recently been described in a case of severe hypofibrinogenemia. 29 Therefore, in our patient, in order to conclude that the single nucleotide change in the last nucleotide of exon 26 is the molecular basis of this patient's Type 2A VWD, we must consider how this change leads not only to skipping of exon 26, but also to skipping of exon 23 in some transcripts.
There is strong evidence to support the theory that order and speed of splicing are important determinants of mRNA transcripts with exon skipping. [30] [31] [32] [33] Despite the fact that the spliceosome associates with the transcript as it emerges from the polymerase, the joining of exons does not occur in order from the 5' end to the 3' end of the transcript. Introns with strong splicing consensus sequences are often removed more efficiently than introns with weaker consensus sequences; thus, some exons located downstream will be joined together before slower splicing, upstream exons. 34 These SR proteins recognize RNA motifs and act to enhance splicing by either directly recruiting the splicing machinery or by antagonizing the action of nearby silencer elements. 35, 36 Exonic splicing silencers (ESS) are not as well understood but seem to work by interacting with negative regulators, often belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family. 37 In our patient, the change at the last nucleotide of exon 26, leading to the skipping of that exon, results in the destruction of an ESE for SRp40 (analysis done using the web based program The expression studies clearly show that the cDNA missing both exon 23 and 26 results in more intracellular retention than the exon 26 skipped construct, however both mutant constructs exhibit a dominant-negative effect on the VWF subunits translated from the normal cDNA, offering an explanation for the severity of the patient's phenotype. The probability that a dimer would contain a mutant subunit is 75%, assuming dimerization in the ER is random. Most of these mutant dimers will be retained within the cell but some dimers containing a mutant subunit may be processed into multimers. One possible explanation for how this might lead to abnormal multimerization is that these mutant subunits may act as reducing-ends during multimer formation; thus additional dimers can only be added to one end of the multimer not both. This would result in a reduction in the size of secreted VWF multimers, which is consistent with the patient's plasma multimer profile. An unexpected finding in our study was that only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From all sizes of multimers were observed in the heterozygous transfection experiments using wild-type and exon-skipped recombinant cDNAs. This discrepancy between the multimer pattern of the heterozygous rVWF proteins and the patient's plasma multimers may well reflect the consequence of several limitations of the recombinant expression system, and is a phenomenon that has been documented in previous similar studies. 40 Examination of the Intron Sequence Information System (ISIS) 41 revealed 109 genes that demonstrated in-frame exon skipping, in one or more exons; however, none of these genes demonstrated skipping of non-adjacent exons. This is the first report that we are aware of in which a change in the last nucleotide of an exon is shown to cause skipping of two non-adjacent exons, and the molecular mechanism demonstrated in this case of Type 2A VWD raises interesting questions about the mechanics of splicing in the VWF gene.
Furthermore, it highlights the importance of examining putative mutations at the mRNA level. only.
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